WUXI BIO (Cayman) Inc. disclosed a minor increase and a larger planned reduction in share capital as of 3 June 2026.

• New shares issued On 2 June 2026, 102,000 ordinary shares were allotted upon exercise of Pre-IPO Share Option Scheme options at HKD 1.72 per share, expanding the issued share base by 0.00246 % to 4.14 billion shares.

• Ongoing share buy-backs Between 27 May and 3 June 2026, the company bought back 7.47 million shares pending cancellation, including 1.51 million shares repurchased on-market on 3 June at prices between HKD 32.52 and HKD 33.82, for a total consideration of HKD 49.89 million.

Cumulatively, 30.65 million shares (0.75 % of the share capital authorised under the current mandate dated 6 June 2025) have been repurchased since the mandate’s adoption. A 30-day moratorium on new share issues runs until 3 July 2026.

• Share capital position Issued shares outstanding: 4,141.01 million Treasury shares: none Shares pending cancellation from recent buy-backs: 7.47 million

All transactions were executed in compliance with Hong Kong Stock Exchange listing rules and the company’s repurchase mandate.